07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1); interleukin-10 (IL-10)

Autoimmune disease INDICATION: Psoriasis Mouse studies suggest inhibiting NFATc1 could help treat psoriasis. In a mouse model of psoriasis, knockout of NFATc1 in B cells increased IL-10 production in the spleen, decreased the number of CD4+ cells...
07:00 , May 21, 2015 |  BC Innovations  |  Targets & Mechanisms

Intersection in marrow

An unlikely connection between Gaucher's disease and multiple myeloma has been uncovered by a U.K. group that found a common node in the pathways responsible for the bone disease symptoms that accompany both diseases. Suppression...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1) In vitro and mouse studies...
07:00 , Jul 29, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML); acute lymphocytic leukemia (ALL) Calcineurin Aa (PPP3CA; CNA1); nuclear factor of activated T cells...
07:00 , Oct 22, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Nuclear...
07:00 , May 28, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease ...
07:00 , Oct 23, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease ...
08:00 , Mar 5, 2007 |  BioCentury  |  Product Development

Beyond 'me better'

Osteoporosis represents one of the paradoxes of modern drug development, where a huge market and the success of current treatments provides few incentives for novel approaches, even though the relatively small number of therapeutic alternatives...
08:00 , Mar 5, 2007 |  BioCentury  |  Product Development

Bone remodeling targets

Bone remodeling targets Bone is continuously broken down by osteoclasts and formed by osteoblasts. Studying this cycle has revealed a number of targets for use as potential treatments for bone diseases like osteoporosis. One of the...